期刊文献+

hPPARγ2高表达细胞模型的建立及与细胞恶性程度的关系

Establishment of hPPARγ2-overexpressing cell model and the relationship with tumor malignancy
原文传递
导出
摘要 目的:构建人过氧化物酶体增殖物激活受体γ2(hPPARγ2)的真核表达载体并建立hPPARγ2高表达细胞株,探讨hPPARγ2表达与肿瘤形成及恶性程度的关系。方法:利用常规分子生物学方法构建hPPARγ2真核表达载体,并转染NIH3T3细胞及人乳腺癌MCF-7,MDA-MB-231细胞。利用细胞穿透人工基底膜实验及致瘤性实验检测转染后细胞恶性程度的改变。采用RT-PCR和Western blot的方法检测hPPARγ2以及ERK,p-ERK的表达情况。结果:成功构建hPPARγ2的真核表达载体并建立了hPPARγ2高表达的细胞模型,转染后的细胞侵袭能力增强、致瘤性增加。结论:hPPARγ2的高表达与肿瘤高侵袭、恶性程度的增高呈正相关。 Objective:To establish hPPARγ2 plasmid and cell lines overexpressing hPPARγ2,then to investigate the relationship of hPPARγ2 with tumor malignancy.Methods:By common methods of molecular biology,hPPARγ2 plasmid was established and stably transfected into cells.The malignancy of the transfected cells was detected by invasion through reconstituted basement membrane assay and oncogenicity assay.The levels of hPPARγ2,ERK,and p-ERK in the stably transfected cells were analyzed by RT-PCR and Western blot assays.Results:In the stably transfected cells,hPPARγ2 increased tumor formation and invasion abilities.These changes related to ERK phosphorylation.Conclusion:hPPARγ2 contributes to tumor formation and tumor growth,which is mediated by the ERK signal pathway.
出处 《中国新药杂志》 CAS CSCD 北大核心 2010年第9期785-792,共8页 Chinese Journal of New Drugs
基金 国家自然科学基金(30371655) 北京市自然科学基金项目(7042040)
关键词 人过氧化物酶体增殖物激活受体γ2 载体构建 侵袭能力 致瘤性 hPPARγ2 establishment of plasmid invasion tumor formation
  • 相关文献

参考文献22

  • 1GREENE ME, BLUMBERG B, MCBRIDE OW, et al. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping[J]. Gene Expr, 1995, 4(4 -5) : 281 -299.
  • 2BEARNER BA, NEGRI C, YEN CJ, et al. Chromosomal localization and partial genomic structure of the human peroxisome proliferators activated receptor-γ (hPPARγ) gene [ J ]. Biochem Biophys Res Commun, 1997, 233 (3) : 756 - 759.
  • 3ZHU Y, QI C, KORENBERG JR, et al. Structural organization of mouse peroxisome proliferatoractivated receptor γ (mPPARγ) gene: alternative promoter use and different splicing yield two mPPARgisoforms [ J ]. Proc Natl Acad Sci USA, 1995, 92 ( 17 ) : 7921 - 7925.
  • 4FAJAS L, AUBOEUF D, RASPE E, et al. The organization, promoter analysis, and expression of the human PPARγ gene [J]. J Biol Chem, 1997, 272(30) : 18779 -18789.
  • 5FAJAS L, FRUCHART JC, AUWERX J. PPARgamma3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter[J]. FEBS Lett, 1998, 438(1 -2):55-60.
  • 6SHIMIZU M, MORIWAKI H. Synergistic effects of PPARγ ligangds and retinoids incancer treatment[ N]. PPAR Research, 2008.
  • 7ISSEMEN I, GREEN S. Activation of a member of the steroid hormone receptor superfamily by pernxisome proliferators [ J ]. Nature, 1990, 347 (6294) :645 - 650.
  • 8BLANQUICENTT C, ROMAN J, HART CM. Thiazolidinediones as anti-cancer agents[J]. Cancer Ther, 2008, 6(A) :25 -34.
  • 9JONES, LP, LI M, HALAMA ED, et al. Promotion of mammary cancer development by tamoxifen in a mouse model of Brcal-mutation-related breast cancer [ J ]. Oncogene, 2005, 24 (22) : 3554 - 2562.
  • 10Ll Y, MENG Y, LI HY, et al. Growth inhibition and differentiation induced by peroxisome proliferator activated receptor gamma ligand resiglitazone in human melanoma cell line A375[J]. Medical Oncology, 2006, 23 (3) :393 - 402.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部